BioNxt Solutions Inc. (CSE:BNXT)
0.5000
-0.0100 (-1.96%)
Apr 10, 2026, 1:01 PM EST
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 11.26K CAD in the quarter ending September 30, 2025, a decrease of -34.17%. This brings the company's revenue in the last twelve months to 15.82K, down -62.34% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
15.82K
Revenue Growth
-62.34%
P/S Ratio
4,093.80
Revenue / Employee
n/a
Employees
20
Market Cap
64.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
| Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
| Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
| Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
| Dec 31, 2020 | 345.65K | 137.54K | 66.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grown Rogue International | 44.46T |
| iAnthus Capital Holdings | 196.87M |
| Planet 13 Holdings | 141.74M |
| Medexus Pharmaceuticals | 136.34M |
| Decibel Cannabis Company | 109.31M |
| Vext Science | 66.63M |
| Rubicon Organics | 59.45M |
| Leef Brands | 47.70M |
BioNxt Solutions News
- 4 days ago - BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries - Accesswire
- 12 days ago - BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy - Accesswire
- 18 days ago - BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform - Accesswire
- 25 days ago - BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe - Accesswire
- 6 weeks ago - BioNxt Announces Closing of Shares for Debt Settlement - Accesswire
- 7 weeks ago - BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis - Accesswire
- 2 months ago - BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery - Accesswire
- 2 months ago - BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion - Accesswire